Aytu BioScience Earnings Call: EXXUA Drives Transition

Aytu BioScience ((AYTU)) has held its Q3 earnings call. Read on for the main highlights of the call.

Aytu BioScience’s latest earnings call painted a cautiously optimistic picture as the company leans into the launch of its new depression drug EXXUA while weathering steep declines in its legacy portfolio. Management emphasized strong early demand, improving access, and attractive unit economics for EXXUA, but acknowledged that the business is still in a transitional phase with pressure on revenue and profitability.

EXXUA Launch Delivers Solid Early Revenue and Script Growth

EXXUA generated $2.4 million in net revenue in what was effectively its first full commercial quarter, giving Aytu a new growth engine as older products fade. Prescriptions climbed from roughly 200 in January to more than 700 in March and rose another 26% in April, surpassing 920 scripts as the launch continues to build momentum.

Rapid Unit Growth Signals Expanding Patient Reach

Gross unit sales of EXXUA reached 3,335 in the quarter, split between 1,807 30‑count bottles and 1,528 titration packs. Since launch, total gross units stand at 3,881, and April shipments alone exceeded 1,300 units, a 51% sequential increase versus March that underscores accelerating uptake through the channel.

Prescriber Adoption Broadens Across the U.S. Market

More than 450 unique prescribers wrote EXXUA during the quarter, representing roughly 10% to 13% of Aytu’s initial 3,500 to 4,000 target prescribers. Scripts have been written in over 40 states, including territories without a dedicated sales presence, suggesting growing word‑of‑mouth and interest among clinicians.

Refill and Titration Patterns Support Early Durability

Management highlighted encouraging signals from refill activity and the use of titration packs, which help patients ramp up dosing. The company is seeing meaningful conversion from starter titration packs to 30‑day prescriptions, with refills beginning to appear despite a small initial patient base, pointing to tolerability and continued treatment.

RxConnect Helps Smooth Access and Boost Approval Rates

The RxConnect program appears to be reducing friction for EXXUA patients by offering a no‑cost 14‑day titration pack and guaranteed coverage for the first two months for commercially insured users. Within this ecosystem, Aytu is seeing prior‑authorization approval rates above 70% and improving coverage across commercial, Medicaid, and Medicare plans.

EXXUA Economics Look Compelling as Volumes Scale

Aytu expects EXXUA to deliver attractive unit economics over time, with cost of goods sold around 31% and a gross contribution margin near 69% before fixed costs. Even after factoring in a 28% royalty and cost true‑ups, management is targeting mid‑ to high‑60% gross margins as scale improves, positioning EXXUA as a key profit driver longer term.

Warrant Amendments Strengthen the Balance Sheet Optics

Amendments to outstanding warrants materially reduced derivative warrant liabilities and boosted stockholders’ equity by $26.4 million at quarter end. As a result, equity rose to $35.1 million as of March 31, 2026, which improves the balance‑sheet presentation and should lower noncash earnings volatility tied to warrant accounting.

Overall Revenue Falls as Legacy Products Retreat

Total net revenue for the quarter fell to $12.4 million from $18.5 million a year earlier, a 33% year‑over‑year decline that reflects the shift in focus toward EXXUA. The new product’s growth is not yet large enough to fully offset the drop in older franchises, leaving the company in a near‑term revenue trough.

ADHD and Pediatric Portfolios Face Sharp Contraction

The ADHD portfolio saw net revenue slide to $9.1 million from $15.4 million, a roughly 41% decline tied to a strategic sales‑force reprioritization and the launch of a generic version of Adzenys. Meanwhile, the pediatric portfolio plunged to $0.9 million from $3.1 million, hurt by unfavorable payer mix, higher rebates, and increased product returns.

Losses Replace Profits as Launch Spend Hits Earnings

Aytu reported a net loss of $5.6 million for the quarter, or $0.53 per share, compared with net income of $4.0 million in the prior‑year period. Adjusted EBITDA swung to a negative $2.8 million from a positive $3.9 million, driven mainly by deliberate EXXUA launch spending layered onto shrinking legacy revenue.

Inventory Write‑Down Weighs on Gross Margin Performance

Gross margin compressed to 61% from 69% a year earlier as the company absorbed a $700,000 inventory write‑down related to the shift to an authorized generic for Adzenys. Excluding that charge, gross margin would have been about 67%, suggesting that underlying profitability remains relatively resilient despite portfolio churn.

Cash Use Rises with Launch Investment and Higher Opex

Cash and equivalents stood at $26.7 million at March 31, 2026, down from $30 million at year‑end, as EXXUA launch investments weighed on the balance sheet. Management plans to keep quarterly sales and marketing at $6 million to $7 million and general and administrative at $5 million to $5.3 million, with an extra $1 million to $2 million of digital spend and modest speaker and education costs next quarter.

Early Gross‑to‑Net Volatility Adds Noise to Reported Results

Executives cautioned that gross‑to‑net adjustments were materially higher than initial assumptions and remain unsettled in the early launch phase. Free titration packs, guaranteed early coverage, and channel stocking can all distort reported revenue and net selling price in the near term, making quarter‑to‑quarter trends harder to interpret.

Authorized Generic Pressure Intensifies on Adzenys

An authorized third‑party generic to Adzenys has already captured about 14% market share after just over four months on the market. That competition is applying additional downward pressure on branded ADHD revenues, especially outside the RxConnect channel, accelerating the decline of one of Aytu’s key legacy products.

Framework for Growth and Profitability as EXXUA Scales

While Aytu did not issue formal guidance, management outlined a framework that hinges on EXXUA’s continued ramp and improving margins. With scripts and units growing strongly, RxConnect supporting access, expected gross margins in the mid‑ to high‑60% range, and operating spend levels now visible, the company is positioning EXXUA as the path toward eventual profitability once scale offsets launch costs and legacy erosion.

Aytu BioScience’s call underscored a business in transition, trading near‑term revenue and earnings pressure for the promise of a higher‑margin growth asset in EXXUA. For investors, the key watch points will be the sustainability of prescription momentum, stabilization of gross‑to‑net dynamics, and how quickly EXXUA’s contribution can outgrow the drag from the shrinking ADHD and pediatric portfolios.